TY - JOUR AU - Lee, C. H. AU - Yelensky, R. AU - Jooss, K. AU - Chan, T. A. PY - 2018 DA - 2018// TI - Update on tumor neoantigens and their utility: why it is good to be different JO - Trends Immunol VL - 39 UR - https://doi.org/10.1016/j.it.2018.04.005 DO - 10.1016/j.it.2018.04.005 ID - Lee2018 ER - TY - JOUR AU - Li, L. AU - Goedegebuure, S. P. AU - Gillanders, W. E. PY - 2017 DA - 2017// TI - Preclinical and clinical development of neoantigen vaccines JO - Ann Oncol VL - 28 UR - https://doi.org/10.1093/annonc/mdx681 DO - 10.1093/annonc/mdx681 ID - Li2017 ER - TY - JOUR AU - Yi, M. AU - Qin, S. AU - Zhao, W. AU - Yu, S. AU - Chu, Q. AU - Wu, K. PY - 2018 DA - 2018// TI - The role of neoantigen in immune checkpoint blockade therapy JO - Exp Hematol Oncol VL - 7 UR - https://doi.org/10.1186/s40164-018-0120-y DO - 10.1186/s40164-018-0120-y ID - Yi2018 ER - TY - JOUR AU - Wagner, S. AU - Mullins, C. S. AU - Linnebacher, M. PY - 2018 DA - 2018// TI - Colorectal cancer vaccines: Tumor-associated antigens vs neoantigens JO - World J Gastroenterol VL - 24 UR - https://doi.org/10.3748/wjg.v24.i48.5418 DO - 10.3748/wjg.v24.i48.5418 ID - Wagner2018 ER - TY - JOUR AU - Keskin, D. B. AU - Anandappa, A. J. AU - Sun, J. AU - Tirosh, I. AU - Mathewson, N. D. AU - Li, S. PY - 2019 DA - 2019// TI - Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial JO - Nature VL - 565 UR - https://doi.org/10.1038/s41586-018-0792-9 DO - 10.1038/s41586-018-0792-9 ID - Keskin2019 ER - TY - JOUR AU - Chen, D. S. AU - Mellman, I. PY - 2013 DA - 2013// TI - Oncology meets immunology: the cancer-immunity cycle JO - Immunity VL - 39 UR - https://doi.org/10.1016/j.immuni.2013.07.012 DO - 10.1016/j.immuni.2013.07.012 ID - Chen2013 ER - TY - JOUR AU - Marin-Acevedo, J. A. AU - Soyano, A. E. AU - Dholaria, B. AU - Knutson, K. L. AU - Lou, Y. PY - 2018 DA - 2018// TI - Cancer immunotherapy beyond immune checkpoint inhibitors JO - J Hematol Oncol VL - 11 UR - https://doi.org/10.1186/s13045-017-0552-6 DO - 10.1186/s13045-017-0552-6 ID - Marin-Acevedo2018 ER - TY - JOUR AU - Chen, D. S. AU - Mellman, I. PY - 2017 DA - 2017// TI - Elements of cancer immunity and the cancer-immune set point JO - Nature VL - 541 UR - https://doi.org/10.1038/nature21349 DO - 10.1038/nature21349 ID - Chen2017 ER - TY - JOUR AU - Long, J. AU - Lin, J. AU - Wang, A. AU - Wu, L. AU - Zheng, Y. AU - Yang, X. PY - 2017 DA - 2017// TI - PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy JO - J Hematol Oncol VL - 10 UR - https://doi.org/10.1186/s13045-017-0511-2 DO - 10.1186/s13045-017-0511-2 ID - Long2017 ER - TY - JOUR AU - Bhatia, A. AU - Kumar, Y. PY - 2014 DA - 2014// TI - Cellular and molecular mechanisms in cancer immune escape: a comprehensive review JO - Expert Rev Clin Immunol VL - 10 UR - https://doi.org/10.1586/1744666X.2014.865519 DO - 10.1586/1744666X.2014.865519 ID - Bhatia2014 ER - TY - JOUR AU - Marin-Acevedo, J. A. AU - Dholaria, B. AU - Soyano, A. E. AU - Knutson, K. L. AU - Chumsri, S. AU - Lou, Y. PY - 2018 DA - 2018// TI - Next generation of immune checkpoint therapy in cancer: new developments and challenges JO - J Hematol Oncol VL - 11 UR - https://doi.org/10.1186/s13045-018-0582-8 DO - 10.1186/s13045-018-0582-8 ID - Marin-Acevedo2018 ER - TY - JOUR AU - Mikkilineni, L. AU - Kochenderfer, J. N. PY - 2017 DA - 2017// TI - Chimeric antigen receptor T-cell therapies for multiple myeloma JO - Blood VL - 130 UR - https://doi.org/10.1182/blood-2017-06-793869 DO - 10.1182/blood-2017-06-793869 ID - Mikkilineni2017 ER - TY - JOUR AU - Rowshanravan, B. AU - Halliday, N. AU - Sansom, D. M. PY - 2018 DA - 2018// TI - CTLA-4: a moving target in immunotherapy JO - Blood VL - 131 ID - Rowshanravan2018 ER - TY - JOUR AU - Yu, S. AU - Li, A. AU - Liu, Q. AU - Li, T. AU - Yuan, X. AU - Han, X. PY - 2017 DA - 2017// TI - Chimeric antigen receptor T cells: a novel therapy for solid tumors JO - J Hematol Oncol VL - 10 UR - https://doi.org/10.1186/s13045-017-0444-9 DO - 10.1186/s13045-017-0444-9 ID - Yu2017 ER - TY - JOUR AU - Horn, L. AU - Mansfield, A. S. AU - Szczesna, A. AU - Havel, L. AU - Krzakowski, M. AU - Hochmair, M. J. PY - 2018 DA - 2018// TI - First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer JO - N Engl J Med VL - 379 UR - https://doi.org/10.1056/NEJMoa1809064 DO - 10.1056/NEJMoa1809064 ID - Horn2018 ER - TY - JOUR AU - Berzofsky, J. A. AU - Terabe, M. AU - Trepel, J. B. AU - Pastan, I. AU - Stroncek, D. F. AU - Morris, J. C. PY - 2018 DA - 2018// TI - Cancer vaccine strategies: translation from mice to human clinical trials JO - Cancer Immunol Immunother VL - 67 UR - https://doi.org/10.1007/s00262-017-2084-x DO - 10.1007/s00262-017-2084-x ID - Berzofsky2018 ER - TY - JOUR AU - Yi, M. AU - Jiao, D. AU - Xu, H. AU - Liu, Q. AU - Zhao, W. AU - Han, X. PY - 2018 DA - 2018// TI - Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors JO - Mol Cancer VL - 17 UR - https://doi.org/10.1186/s12943-018-0864-3 DO - 10.1186/s12943-018-0864-3 ID - Yi2018 ER - TY - JOUR AU - Wang, Z. AU - Wu, Z. AU - Liu, Y. AU - Han, W. PY - 2017 DA - 2017// TI - New development in CAR-T cell therapy JO - J Hematol Oncol VL - 10 UR - https://doi.org/10.1186/s13045-017-0423-1 DO - 10.1186/s13045-017-0423-1 ID - Wang2017 ER - TY - JOUR AU - Liu, D. AU - Wang, S. AU - Bindeman, W. PY - 2017 DA - 2017// TI - Clinical applications of PD-L1 bioassays for cancer immunotherapy JO - J Hematol Oncol VL - 10 UR - https://doi.org/10.1186/s13045-017-0479-y DO - 10.1186/s13045-017-0479-y ID - Liu2017 ER - TY - JOUR AU - Yi, M. AU - Jiao, D. AU - Qin, S. AU - Chu, Q. AU - Wu, K. AU - Li, A. PY - 2019 DA - 2019// TI - Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment JO - Mol Cancer VL - 18 UR - https://doi.org/10.1186/s12943-019-0974-6 DO - 10.1186/s12943-019-0974-6 ID - Yi2019 ER - TY - JOUR AU - Li, A. AU - Yi, M. AU - Qin, S. AU - Song, Y. AU - Chu, Q. AU - Wu, K. PY - 2019 DA - 2019// TI - Activating cGAS-STING pathway for the optimal effect of cancer immunotherapy JO - J Hematol Oncol VL - 12 UR - https://doi.org/10.1186/s13045-019-0721-x DO - 10.1186/s13045-019-0721-x ID - Li2019 ER - TY - JOUR AU - Eustermann, S. AU - Wu, W. F. AU - Langelier, M. F. AU - Yang, J. C. AU - Easton, L. E. AU - Riccio, A. A. PY - 2015 DA - 2015// TI - Structural basis of detection and signaling of DNA single-strand breaks by human PARP-1 JO - Mol Cell VL - 60 UR - https://doi.org/10.1016/j.molcel.2015.10.032 DO - 10.1016/j.molcel.2015.10.032 ID - Eustermann2015 ER - TY - JOUR AU - Stewart, R. A. AU - Pilie, P. G. AU - Yap, T. A. PY - 2018 DA - 2018// TI - Development of PARP and immune-checkpoint inhibitor combinations JO - Cancer Res VL - 78 UR - https://doi.org/10.1158/0008-5472.CAN-18-2652 DO - 10.1158/0008-5472.CAN-18-2652 ID - Stewart2018 ER - TY - JOUR AU - Jiao, S. AU - Xia, W. AU - Yamaguchi, H. AU - Wei, Y. AU - Chen, M. K. AU - Hsu, J. M. PY - 2017 DA - 2017// TI - PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression JO - Clin Cancer Res VL - 23 UR - https://doi.org/10.1158/1078-0432.CCR-16-3215 DO - 10.1158/1078-0432.CCR-16-3215 ID - Jiao2017 ER - TY - JOUR AU - Sirbu, B. M. AU - Cortez, D. PY - 2013 DA - 2013// TI - DNA damage response: three levels of DNA repair regulation JO - Cold Spring Harb Perspect Biol VL - 5 UR - https://doi.org/10.1101/cshperspect.a012724 DO - 10.1101/cshperspect.a012724 ID - Sirbu2013 ER - TY - JOUR AU - Jackson, S. P. AU - Bartek, J. PY - 2009 DA - 2009// TI - The DNA-damage response in human biology and disease JO - Nature VL - 461 UR - https://doi.org/10.1038/nature08467 DO - 10.1038/nature08467 ID - Jackson2009 ER - TY - JOUR AU - Brown, J. S. AU - O’Carrigan, B. AU - Jackson, S. P. AU - Yap, T. A. PY - 2017 DA - 2017// TI - Targeting DNA repair in cancer: beyond PARP inhibitors JO - Cancer Discov VL - 7 UR - https://doi.org/10.1158/2159-8290.CD-16-0860 DO - 10.1158/2159-8290.CD-16-0860 ID - Brown2017 ER - TY - JOUR AU - Tubbs, A. AU - Nussenzweig, A. PY - 2017 DA - 2017// TI - Endogenous DNA damage as a source of genomic instability in cancer JO - Cell VL - 168 UR - https://doi.org/10.1016/j.cell.2017.01.002 DO - 10.1016/j.cell.2017.01.002 ID - Tubbs2017 ER - TY - JOUR AU - Lord, C. J. AU - Ashworth, A. PY - 2017 DA - 2017// TI - PARP inhibitors: synthetic lethality in the clinic JO - Science VL - 355 UR - https://doi.org/10.1126/science.aam7344 DO - 10.1126/science.aam7344 ID - Lord2017 ER - TY - JOUR AU - Vos, M. AU - Schreiber, V. AU - Dantzer, F. PY - 2012 DA - 2012// TI - The diverse roles and clinical relevance of PARPs in DNA damage repair: current state of the art JO - Biochem Pharmacol VL - 84 UR - https://doi.org/10.1016/j.bcp.2012.03.018 DO - 10.1016/j.bcp.2012.03.018 ID - Vos2012 ER - TY - JOUR AU - Liu, L. AU - Kong, M. AU - Gassman, N. R. AU - Freudenthal, B. D. AU - Prasad, R. AU - Zhen, S. PY - 2017 DA - 2017// TI - PARP1 changes from three-dimensional DNA damage searching to one-dimensional diffusion after auto-PARylation or in the presence of APE1 JO - Nucleic Acids Res VL - 45 UR - https://doi.org/10.1093/nar/gkx1047 DO - 10.1093/nar/gkx1047 ID - Liu2017 ER - TY - JOUR AU - Wang, Y. Q. AU - Wang, P. Y. AU - Wang, Y. T. AU - Yang, G. F. AU - Zhang, A. AU - Miao, Z. H. PY - 2016 DA - 2016// TI - An update on Poly(ADP-ribose)polymerase-1 (PARP-1) inhibitors: opportunities and challenges in cancer therapy JO - J Med Chem VL - 59 UR - https://doi.org/10.1021/acs.jmedchem.6b00055 DO - 10.1021/acs.jmedchem.6b00055 ID - Wang2016 ER - TY - JOUR AU - Pettitt, S. J. AU - Lord, C. J. PY - 2019 DA - 2019// TI - Dissecting PARP inhibitor resistance with functional genomics JO - Curr Opin Genet Dev VL - 54 UR - https://doi.org/10.1016/j.gde.2019.03.001 DO - 10.1016/j.gde.2019.03.001 ID - Pettitt2019 ER - TY - JOUR AU - Farmer, H. AU - McCabe, N. AU - Lord, C. J. AU - Tutt, A. N. AU - Johnson, D. A. AU - Richardson, T. B. PY - 2005 DA - 2005// TI - Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy JO - Nature VL - 434 UR - https://doi.org/10.1038/nature03445 DO - 10.1038/nature03445 ID - Farmer2005 ER - TY - JOUR AU - Bergs, J. W. AU - Krawczyk, P. M. AU - Borovski, T. AU - Cate, R. AU - Rodermond, H. M. AU - Stap, J. PY - 2013 DA - 2013// TI - Inhibition of homologous recombination by hyperthermia shunts early double strand break repair to non-homologous end-joining JO - DNA Repair (Amst) VL - 12 UR - https://doi.org/10.1016/j.dnarep.2012.10.008 DO - 10.1016/j.dnarep.2012.10.008 ID - Bergs2013 ER - TY - JOUR AU - Agarwal, S. AU - Tafel, A. A. AU - Kanaar, R. PY - 2006 DA - 2006// TI - DNA double-strand break repair and chromosome translocations JO - DNA Repair (Amst) VL - 5 UR - https://doi.org/10.1016/j.dnarep.2006.05.029 DO - 10.1016/j.dnarep.2006.05.029 ID - Agarwal2006 ER - TY - JOUR AU - Faraoni, I. s. a. b. e. l. l. a. AU - Graziani, G. r. a. z. i. a. PY - 2018 DA - 2018// TI - Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors JO - Cancers VL - 10 UR - https://doi.org/10.3390/cancers10120487 DO - 10.3390/cancers10120487 ID - Faraoni2018 ER - TY - JOUR AU - Povirk, L. F. PY - 2006 DA - 2006// TI - Biochemical mechanisms of chromosomal translocations resulting from DNA double-strand breaks JO - DNA Repair (Amst) VL - 5 UR - https://doi.org/10.1016/j.dnarep.2006.05.016 DO - 10.1016/j.dnarep.2006.05.016 ID - Povirk2006 ER - TY - JOUR AU - Lowery, M. A. AU - Kelsen, D. P. AU - Capanu, M. AU - Smith, S. C. AU - Lee, J. W. AU - Stadler, Z. K. PY - 2018 DA - 2018// TI - Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma JO - Eur J Cancer VL - 89 UR - https://doi.org/10.1016/j.ejca.2017.11.004 DO - 10.1016/j.ejca.2017.11.004 ID - Lowery2018 ER - TY - JOUR AU - Swisher, E. M. AU - Lin, K. K. AU - Oza, A. M. AU - Scott, C. L. AU - Giordano, H. AU - Sun, J. PY - 2017 DA - 2017// TI - Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial JO - Lancet Oncol VL - 18 UR - https://doi.org/10.1016/S1470-2045(16)30559-9 DO - 10.1016/S1470-2045(16)30559-9 ID - Swisher2017 ER - TY - JOUR AU - Robson, M. AU - Im, S. A. AU - Senkus, E. AU - Xu, B. AU - Domchek, S. M. AU - Masuda, N. PY - 2017 DA - 2017// TI - Olaparib for metastatic breast cancer in patients with a germline BRCA mutation JO - N Engl J Med VL - 377 UR - https://doi.org/10.1056/NEJMoa1706450 DO - 10.1056/NEJMoa1706450 ID - Robson2017 ER - TY - JOUR AU - Pujade-Lauraine, E. AU - Ledermann, J. A. AU - Selle, F. AU - Gebski, V. AU - Penson, R. T. AU - Oza, A. M. PY - 2017 DA - 2017// TI - Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial JO - Lancet Oncol VL - 18 UR - https://doi.org/10.1016/S1470-2045(17)30469-2 DO - 10.1016/S1470-2045(17)30469-2 ID - Pujade-Lauraine2017 ER - TY - JOUR AU - Mirza, M. R. AU - Monk, B. J. AU - Herrstedt, J. AU - Oza, A. M. AU - Mahner, S. AU - Redondo, A. PY - 2016 DA - 2016// TI - Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer JO - N Engl J Med VL - 375 UR - https://doi.org/10.1056/NEJMoa1611310 DO - 10.1056/NEJMoa1611310 ID - Mirza2016 ER - TY - JOUR AU - Turner, N. C. AU - Telli, M. L. AU - Rugo, H. S. AU - Mailliez, A. AU - Ettl, J. AU - Grischke, E. M. PY - 2019 DA - 2019// TI - A phase II study of talazoparib after platinum or cytotoxic nonplatinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations (ABRAZO) JO - Clin Cancer Res VL - 25 UR - https://doi.org/10.1158/1078-0432.CCR-18-1891 DO - 10.1158/1078-0432.CCR-18-1891 ID - Turner2019 ER - TY - JOUR AU - Murai, J. AU - Huang, S. Y. AU - Das, B. B. AU - Renaud, A. AU - Zhang, Y. AU - Doroshow, J. H. PY - 2012 DA - 2012// TI - Trapping of PARP1 and PARP2 by clinical PARP inhibitors JO - Cancer Res VL - 72 UR - https://doi.org/10.1158/0008-5472.CAN-12-2753 DO - 10.1158/0008-5472.CAN-12-2753 ID - Murai2012 ER - TY - JOUR AU - Helleday, T. PY - 2011 DA - 2011// TI - The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings JO - Mol Oncol VL - 5 UR - https://doi.org/10.1016/j.molonc.2011.07.001 DO - 10.1016/j.molonc.2011.07.001 ID - Helleday2011 ER - TY - JOUR AU - Franzese, E. AU - Centonze, S. AU - Diana, A. AU - Carlino, F. AU - Guerrera, L. P. AU - Napoli, M. PY - 2019 DA - 2019// TI - PARP inhibitors in ovarian cancer JO - Cancer Treat Rev VL - 73 UR - https://doi.org/10.1016/j.ctrv.2018.12.002 DO - 10.1016/j.ctrv.2018.12.002 ID - Franzese2019 ER - TY - JOUR AU - Dulaney, C. AU - Marcrom, S. AU - Stanley, J. AU - Yang, E. S. PY - 2017 DA - 2017// TI - Poly(ADP-ribose) polymerase activity and inhibition in cancer JO - Semin Cell Dev Biol VL - 63 UR - https://doi.org/10.1016/j.semcdb.2017.01.007 DO - 10.1016/j.semcdb.2017.01.007 ID - Dulaney2017 ER - TY - JOUR AU - Hu, X. AU - Huang, W. AU - Fan, M. PY - 2017 DA - 2017// TI - Emerging therapies for breast cancer JO - J Hematol Oncol VL - 10 UR - https://doi.org/10.1186/s13045-017-0466-3 DO - 10.1186/s13045-017-0466-3 ID - Hu2017 ER - TY - JOUR AU - Lord, C. J. AU - Ashworth, A. PY - 2016 DA - 2016// TI - BRCAness revisited JO - Nat Rev Cancer VL - 16 UR - https://doi.org/10.1038/nrc.2015.21 DO - 10.1038/nrc.2015.21 ID - Lord2016 ER - TY - JOUR AU - Lord, C. J. AU - Ashworth, A. PY - 2013 DA - 2013// TI - Mechanisms of resistance to therapies targeting BRCA-mutant cancers JO - Nat Med VL - 19 UR - https://doi.org/10.1038/nm.3369 DO - 10.1038/nm.3369 ID - Lord2013 ER - TY - JOUR AU - Jaspers, J. E. AU - Kersbergen, A. AU - Boon, U. AU - Sol, W. AU - Deemter, L. AU - Zander, S. A. PY - 2013 DA - 2013// TI - Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors JO - Cancer Discov VL - 3 UR - https://doi.org/10.1158/2159-8290.CD-12-0049 DO - 10.1158/2159-8290.CD-12-0049 ID - Jaspers2013 ER - TY - JOUR AU - Pettitt, S. J. AU - Rehman, F. L. AU - Bajrami, I. AU - Brough, R. AU - Wallberg, F. AU - Kozarewa, I. PY - 2013 DA - 2013// TI - A genetic screen using the PiggyBac transposon in haploid cells identifies Parp1 as a mediator of olaparib toxicity JO - PLoS One VL - 8 UR - https://doi.org/10.1371/journal.pone.0061520 DO - 10.1371/journal.pone.0061520 ID - Pettitt2013 ER - TY - JOUR AU - Barber, L. J. AU - Sandhu, S. AU - Chen, L. AU - Campbell, J. AU - Kozarewa, I. AU - Fenwick, K. PY - 2013 DA - 2013// TI - Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor JO - J Pathol VL - 229 UR - https://doi.org/10.1002/path.4140 DO - 10.1002/path.4140 ID - Barber2013 ER - TY - JOUR AU - Dhawan, M. S. AU - Bartelink, I. H. AU - Aggarwal, R. R. AU - Leng, J. AU - Zhang, J. Z. AU - Pawlowska, N. PY - 2017 DA - 2017// TI - Differential toxicity in patients with and without DNA repair mutations: phase I study of carboplatin and talazoparib in advanced solid tumors JO - Clin Cancer Res VL - 23 UR - https://doi.org/10.1158/1078-0432.CCR-17-0703 DO - 10.1158/1078-0432.CCR-17-0703 ID - Dhawan2017 ER - TY - JOUR AU - Esteva, F. J. AU - Hubbard-Lucey, V. M. AU - Tang, J. AU - Pusztai, L. PY - 2019 DA - 2019// TI - Immunotherapy and targeted therapy combinations in metastatic breast cancer JO - Lancet Oncol VL - 20 UR - https://doi.org/10.1016/S1470-2045(19)30026-9 DO - 10.1016/S1470-2045(19)30026-9 ID - Esteva2019 ER - TY - JOUR AU - Moore, K. AU - Colombo, N. AU - Scambia, G. AU - Kim, B. G. AU - Oaknin, A. AU - Friedlander, M. PY - 2018 DA - 2018// TI - Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer JO - N Engl J Med VL - 379 UR - https://doi.org/10.1056/NEJMoa1810858 DO - 10.1056/NEJMoa1810858 ID - Moore2018 ER - TY - JOUR AU - Golan, T. a. l. i. a. AU - Hammel, P. a. s. c. a. l. AU - Reni, M. i. c. h. e. l. e. AU - Van Cutsem, E. r. i. c. AU - Macarulla, T. e. r. e. s. a. AU - Hall, M. i. c. h. a. e. l. J. AU - Park, J. o. o. n. -. O. h. AU - Hochhauser, D. a. n. i. e. l. AU - Arnold, D. i. r. k. AU - Oh, D. o. -. Y. o. u. n. AU - Reinacher-Schick, A. n. k. e. AU - Tortora, G. i. a. m. p. a. o. l. o. AU - Algül, H. a. n. a. AU - O’Reilly, E. i. l. e. e. n. M. AU - McGuinness, D. a. v. i. d. AU - Cui, K. a. r. e. n. Y. AU - Schlienger, K. a. t. i. a. AU - Locker, G. e. r. s. h. o. n. Y. AU - Kindler, H. e. d. y. L. PY - 2019 DA - 2019// TI - Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer JO - New England Journal of Medicine VL - 381 UR - https://doi.org/10.1056/NEJMoa1903387 DO - 10.1056/NEJMoa1903387 ID - Golan2019 ER - TY - JOUR AU - Bretscher, P. A. PY - 1999 DA - 1999// TI - A two-step, two-signal model for the primary activation of precursor helper T cells JO - Proc Natl Acad Sci U S A VL - 96 UR - https://doi.org/10.1073/pnas.96.1.185 DO - 10.1073/pnas.96.1.185 ID - Bretscher1999 ER - TY - JOUR AU - Appleman, L. J. AU - Boussiotis, V. A. PY - 2003 DA - 2003// TI - T cell anergy and costimulation JO - Immunol Rev VL - 192 UR - https://doi.org/10.1034/j.1600-065X.2003.00009.x DO - 10.1034/j.1600-065X.2003.00009.x ID - Appleman2003 ER - TY - JOUR AU - Oosterwegel, M. A. AU - Greenwald, R. J. AU - Mandelbrot, D. A. AU - Lorsbach, R. B. AU - Sharpe, A. H. PY - 1999 DA - 1999// TI - CTLA-4 and T cell activation JO - Curr Opin Immunol VL - 11 UR - https://doi.org/10.1016/S0952-7915(99)80047-8 DO - 10.1016/S0952-7915(99)80047-8 ID - Oosterwegel1999 ER - TY - JOUR AU - Salomon, B. AU - Bluestone, J. A. PY - 2001 DA - 2001// TI - Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation JO - Annu Rev Immunol VL - 19 UR - https://doi.org/10.1146/annurev.immunol.19.1.225 DO - 10.1146/annurev.immunol.19.1.225 ID - Salomon2001 ER - TY - JOUR AU - Yamazaki, T. AU - Akiba, H. AU - Iwai, H. AU - Matsuda, H. AU - Aoki, M. AU - Tanno, Y. PY - 2002 DA - 2002// TI - Expression of programmed death 1 ligands by murine T cells and APC JO - J Immunol. VL - 169 UR - https://doi.org/10.4049/jimmunol.169.10.5538 DO - 10.4049/jimmunol.169.10.5538 ID - Yamazaki2002 ER - TY - JOUR AU - Keir, M. E. AU - Butte, M. J. AU - Freeman, G. J. AU - Sharpe, A. H. PY - 2008 DA - 2008// TI - PD-1 and its ligands in tolerance and immunity JO - Annu Rev Immunol VL - 26 UR - https://doi.org/10.1146/annurev.immunol.26.021607.090331 DO - 10.1146/annurev.immunol.26.021607.090331 ID - Keir2008 ER - TY - JOUR AU - Bardhan, K. AU - Anagnostou, T. AU - Boussiotis, V. A. PY - 2016 DA - 2016// TI - The PD1:PD-L1/2 pathway from discovery to clinical implementation JO - Front Immunol VL - 7 UR - https://doi.org/10.3389/fimmu.2016.00550 DO - 10.3389/fimmu.2016.00550 ID - Bardhan2016 ER - TY - JOUR AU - Boussiotis, V. A. AU - Chatterjee, P. AU - Li, L. PY - 2014 DA - 2014// TI - Biochemical signaling of PD-1 on T cells and its functional implications JO - Cancer J VL - 20 UR - https://doi.org/10.1097/PPO.0000000000000059 DO - 10.1097/PPO.0000000000000059 ID - Boussiotis2014 ER - TY - JOUR AU - Sheppard, K. A. AU - Fitz, L. J. AU - Lee, J. M. AU - Benander, C. AU - George, J. A. AU - Wooters, J. PY - 2004 DA - 2004// TI - PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta JO - FEBS Lett VL - 574 UR - https://doi.org/10.1016/j.febslet.2004.07.083 DO - 10.1016/j.febslet.2004.07.083 ID - Sheppard2004 ER - TY - JOUR AU - Patsoukis, N. AU - Brown, J. AU - Petkova, V. AU - Liu, F. AU - Li, L. AU - Boussiotis, V. A. PY - 2012 DA - 2012// TI - Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation JO - Sci Signal VL - 5 UR - https://doi.org/10.1126/scisignal.2002796 DO - 10.1126/scisignal.2002796 ID - Patsoukis2012 ER - TY - JOUR AU - Parry, R. V. AU - Chemnitz, J. M. AU - Frauwirth, K. A. AU - Lanfranco, A. R. AU - Braunstein, I. AU - Kobayashi, S. V. PY - 2005 DA - 2005// TI - CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms JO - Mol Cell Biol VL - 25 UR - https://doi.org/10.1128/MCB.25.21.9543-9553.2005 DO - 10.1128/MCB.25.21.9543-9553.2005 ID - Parry2005 ER - TY - JOUR AU - Chang, C. H. AU - Curtis, J. D. AU - Maggi, L. B. AU - Faubert, B. AU - Villarino, A. V. AU - O’Sullivan, D. PY - 2013 DA - 2013// TI - Posttranscriptional control of T cell effector function by aerobic glycolysis JO - Cell VL - 153 UR - https://doi.org/10.1016/j.cell.2013.05.016 DO - 10.1016/j.cell.2013.05.016 ID - Chang2013 ER - TY - JOUR AU - Wilson, R. A. M. AU - Evans, T. R. J. AU - Fraser, A. R. AU - Nibbs, R. J. B. PY - 2018 DA - 2018// TI - Immune checkpoint inhibitors: new strategies to checkmate cancer JO - Clin Exp Immunol VL - 191 UR - https://doi.org/10.1111/cei.13081 DO - 10.1111/cei.13081 ID - Wilson2018 ER - TY - JOUR AU - Ok, C. Y. AU - Young, K. H. PY - 2017 DA - 2017// TI - Checkpoint inhibitors in hematological malignancies JO - J Hematol Oncol VL - 10 UR - https://doi.org/10.1186/s13045-017-0474-3 DO - 10.1186/s13045-017-0474-3 ID - Ok2017 ER - TY - JOUR AU - Soskic, B. AU - Qureshi, O. S. AU - Hou, T. AU - Sansom, D. M. PY - 2014 DA - 2014// TI - A transendocytosis perspective on the CD28/CTLA-4 pathway JO - Adv Immunol VL - 124 UR - https://doi.org/10.1016/B978-0-12-800147-9.00004-2 DO - 10.1016/B978-0-12-800147-9.00004-2 ID - Soskic2014 ER - TY - JOUR AU - Rudd, C. E. AU - Taylor, A. AU - Schneider, H. PY - 2009 DA - 2009// TI - CD28 and CTLA-4 coreceptor expression and signal transduction JO - Immunol Rev VL - 229 UR - https://doi.org/10.1111/j.1600-065X.2009.00770.x DO - 10.1111/j.1600-065X.2009.00770.x ID - Rudd2009 ER - TY - JOUR AU - Robert, C. AU - Thomas, L. AU - Bondarenko, I. AU - O’Day, S. AU - Weber, J. AU - Garbe, C. PY - 2011 DA - 2011// TI - Ipilimumab plus dacarbazine for previously untreated metastatic melanoma JO - N Engl J Med VL - 364 UR - https://doi.org/10.1056/NEJMoa1104621 DO - 10.1056/NEJMoa1104621 ID - Robert2011 ER - TY - JOUR AU - Mehta, K. AU - Patel, K. AU - Parikh, R. A. PY - 2017 DA - 2017// TI - Immunotherapy in genitourinary malignancies JO - J Hematol Oncol. VL - 10 UR - https://doi.org/10.1186/s13045-017-0457-4 DO - 10.1186/s13045-017-0457-4 ID - Mehta2017 ER - TY - JOUR AU - Nanda, R. AU - Chow, L. Q. AU - Dees, E. C. AU - Berger, R. AU - Gupta, S. AU - Geva, R. PY - 2016 DA - 2016// TI - Pembrolizumab in patients with advanced triple-negative breast cancer: Phase Ib KEYNOTE-012 Study JO - J Clin Oncol VL - 34 UR - https://doi.org/10.1200/JCO.2015.64.8931 DO - 10.1200/JCO.2015.64.8931 ID - Nanda2016 ER - TY - JOUR AU - Forde, P. M. AU - Chaft, J. E. AU - Smith, K. N. AU - Anagnostou, V. AU - Cottrell, T. R. AU - Hellmann, M. D. PY - 2018 DA - 2018// TI - Neoadjuvant PD-1 blockade in resectable lung cancer JO - N Engl J Med. VL - 378 UR - https://doi.org/10.1056/NEJMoa1716078 DO - 10.1056/NEJMoa1716078 ID - Forde2018 ER - TY - JOUR AU - Atkins, M. B. AU - Plimack, E. R. AU - Puzanov, I. AU - Fishman, M. N. AU - McDermott, D. F. AU - Cho, D. C. PY - 2018 DA - 2018// TI - Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial JO - Lancet Oncol VL - 19 UR - https://doi.org/10.1016/S1470-2045(18)30081-0 DO - 10.1016/S1470-2045(18)30081-0 ID - Atkins2018 ER - TY - JOUR AU - Eggermont, A. M. M. AU - Blank, C. U. AU - Mandala, M. AU - Long, G. V. AU - Atkinson, V. AU - Dalle, S. PY - 2018 DA - 2018// TI - Adjuvant pembrolizumab versus placebo in resected stage III melanoma JO - N Engl J Med VL - 378 UR - https://doi.org/10.1056/NEJMoa1802357 DO - 10.1056/NEJMoa1802357 ID - Eggermont2018 ER - TY - JOUR AU - Massard, C. AU - Gordon, M. S. AU - Sharma, S. AU - Rafii, S. AU - Wainberg, Z. A. AU - Luke, J. PY - 2016 DA - 2016// TI - Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death Ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer JO - J Clin Oncol VL - 34 UR - https://doi.org/10.1200/JCO.2016.67.9761 DO - 10.1200/JCO.2016.67.9761 ID - Massard2016 ER - TY - JOUR AU - Xu-Monette, Z. Y. AU - Zhang, M. AU - Li, J. AU - Young, K. H. PY - 2017 DA - 2017// TI - PD-1/PD-L1 Blockade: have we found the key to unleash the antitumor immune response? JO - Front Immunol VL - 8 UR - https://doi.org/10.3389/fimmu.2017.01597 DO - 10.3389/fimmu.2017.01597 ID - Xu-Monette2017 ER - TY - JOUR AU - Yarchoan, M. AU - Hopkins, A. AU - Jaffee, E. M. PY - 2017 DA - 2017// TI - Tumor mutational burden and response rate to PD-1 inhibition JO - N Engl J Med VL - 377 UR - https://doi.org/10.1056/NEJMc1713444 DO - 10.1056/NEJMc1713444 ID - Yarchoan2017 ER - TY - JOUR AU - Jin, Z. AU - Yoon, H. H. PY - 2016 DA - 2016// TI - The promise of PD-1 inhibitors in gastro-esophageal cancers: microsatellite instability vs. PD-L1 JO - J Gastrointest Oncol VL - 7 UR - https://doi.org/10.21037/jgo.2016.08.06 DO - 10.21037/jgo.2016.08.06 ID - Jin2016 ER - TY - JOUR AU - Teng, M. W. AU - Ngiow, S. F. AU - Ribas, A. AU - Smyth, M. J. PY - 2015 DA - 2015// TI - Classifying cancers based on T-cell infiltration and PD-L1 JO - Cancer Res VL - 75 UR - https://doi.org/10.1158/0008-5472.CAN-15-0255 DO - 10.1158/0008-5472.CAN-15-0255 ID - Teng2015 ER - TY - JOUR AU - Reck, M. AU - Rodriguez-Abreu, D. AU - Robinson, A. G. AU - Hui, R. AU - Csoszi, T. AU - Fulop, A. PY - 2016 DA - 2016// TI - Pembrolizumab versus Chemotherapy for PD-L1-positive non-small-cell lung cancer JO - N Engl J Med VL - 375 UR - https://doi.org/10.1056/NEJMoa1606774 DO - 10.1056/NEJMoa1606774 ID - Reck2016 ER - TY - JOUR AU - Gong, X. AU - Li, X. AU - Jiang, T. AU - Xie, H. AU - Zhu, Z. AU - Zhou, F. PY - 2017 DA - 2017// TI - Combined radiotherapy and anti-PD-L1 antibody synergistically enhances antitumor effect in non-small cell lung cancer JO - J Thorac Oncol VL - 12 UR - https://doi.org/10.1016/j.jtho.2017.04.014 DO - 10.1016/j.jtho.2017.04.014 ID - Gong2017 ER - TY - JOUR AU - Dafni, U. AU - Tsourti, Z. AU - Vervita, K. AU - Peters, S. PY - 2019 DA - 2019// TI - Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis JO - Lung Cancer VL - 134 UR - https://doi.org/10.1016/j.lungcan.2019.05.029 DO - 10.1016/j.lungcan.2019.05.029 ID - Dafni2019 ER - TY - JOUR AU - Sullivan, R. J. AU - Hamid, O. AU - Gonzalez, R. AU - Infante, J. R. AU - Patel, M. R. AU - Hodi, F. S. PY - 2019 DA - 2019// TI - Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients JO - Nat Med VL - 25 UR - https://doi.org/10.1038/s41591-019-0474-7 DO - 10.1038/s41591-019-0474-7 ID - Sullivan2019 ER - TY - JOUR AU - Chowdhury, P. S. AU - Chamoto, K. AU - Honjo, T. PY - 2018 DA - 2018// TI - Combination therapy strategies for improving PD-1 blockade efficacy: a new era in cancer immunotherapy JO - J Intern Med VL - 283 UR - https://doi.org/10.1111/joim.12708 DO - 10.1111/joim.12708 ID - Chowdhury2018 ER - TY - JOUR AU - Migden, M. R. AU - Rischin, D. AU - Schmults, C. D. AU - Guminski, A. AU - Hauschild, A. AU - Lewis, K. D. PY - 2018 DA - 2018// TI - PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma JO - N Engl J Med VL - 379 UR - https://doi.org/10.1056/NEJMoa1805131 DO - 10.1056/NEJMoa1805131 ID - Migden2018 ER - TY - JOUR AU - Pilie, P. G. AU - Gay, C. M. AU - Byers, L. A. AU - O’Connor, M. J. AU - Yap, T. A. PY - 2019 DA - 2019// TI - PARP inhibitors: extending benefit beyond BRCA-mutant cancers JO - Clin Cancer Res VL - 25 UR - https://doi.org/10.1158/1078-0432.CCR-18-0968 DO - 10.1158/1078-0432.CCR-18-0968 ID - Pilie2019 ER - TY - JOUR AU - Mehnert, J. M. AU - Panda, A. AU - Zhong, H. AU - Hirshfield, K. AU - Damare, S. AU - Lane, K. PY - 2016 DA - 2016// TI - Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer JO - J Clin Invest VL - 126 UR - https://doi.org/10.1172/JCI84940 DO - 10.1172/JCI84940 ID - Mehnert2016 ER - TY - JOUR AU - Strickland, K. C. AU - Howitt, B. E. AU - Shukla, S. A. AU - Rodig, S. AU - Ritterhouse, L. L. AU - Liu, J. F. PY - 2016 DA - 2016// TI - Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer JO - Oncotarget VL - 7 UR - https://doi.org/10.18632/oncotarget.7277 DO - 10.18632/oncotarget.7277 ID - Strickland2016 ER - TY - JOUR AU - Teo, M. Y. AU - Seier, K. AU - Ostrovnaya, I. AU - Regazzi, A. M. AU - Kania, B. E. AU - Moran, M. M. PY - 2018 DA - 2018// TI - Alterations in DNA damage response and repair genes as potential marker of clinical benefit from PD-1/PD-L1 blockade in advanced urothelial cancers JO - J Clin Oncol VL - 36 UR - https://doi.org/10.1200/JCO.2017.75.7740 DO - 10.1200/JCO.2017.75.7740 ID - Teo2018 ER - TY - JOUR AU - Mouw, K. W. AU - Goldberg, M. S. AU - Konstantinopoulos, P. A. AU - D’Andrea, A. D. PY - 2017 DA - 2017// TI - DNA damage and repair biomarkers of immunotherapy response JO - Cancer Discov VL - 7 UR - https://doi.org/10.1158/2159-8290.CD-17-0226 DO - 10.1158/2159-8290.CD-17-0226 ID - Mouw2017 ER - TY - STD TI - Khoo LT, Chen LY. Role of the cGAS-STING pathway in cancer development and oncotherapeutic approaches. EMBO Rep. 2018. https://doi.org/10.15252/embr.201846935. ID - ref97 ER - TY - JOUR AU - Gao, P. AU - Ascano, M. AU - Wu, Y. AU - Barchet, W. AU - Gaffney, B. L. AU - Zillinger, T. PY - 2013 DA - 2013// TI - Cyclic [G(2’,5’)pA(3’,5’)p] is the metazoan second messenger produced by DNA-activated cyclic GMP-AMP synthase JO - Cell VL - 153 UR - https://doi.org/10.1016/j.cell.2013.04.046 DO - 10.1016/j.cell.2013.04.046 ID - Gao2013 ER - TY - JOUR AU - Barber, G. N. PY - 2015 DA - 2015// TI - STING: infection, inflammation and cancer JO - Nat Rev Immunol VL - 15 UR - https://doi.org/10.1038/nri3921 DO - 10.1038/nri3921 ID - Barber2015 ER - TY - JOUR AU - Ishikawa, H. AU - Ma, Z. AU - Barber, G. N. PY - 2009 DA - 2009// TI - STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity JO - Nature VL - 461 UR - https://doi.org/10.1038/nature08476 DO - 10.1038/nature08476 ID - Ishikawa2009 ER - TY - JOUR AU - Abe, T. AU - Barber, G. N. PY - 2014 DA - 2014// TI - Cytosolic-DNA-mediated, STING-dependent proinflammatory gene induction necessitates canonical NF-kappaB activation through TBK1 JO - J Virol VL - 88 UR - https://doi.org/10.1128/JVI.00037-14 DO - 10.1128/JVI.00037-14 ID - Abe2014 ER - TY - JOUR AU - Zitvogel, L. AU - Galluzzi, L. AU - Kepp, O. AU - Smyth, M. J. AU - Kroemer, G. PY - 2015 DA - 2015// TI - Type I interferons in anticancer immunity JO - Nat Rev Immunol VL - 15 UR - https://doi.org/10.1038/nri3845 DO - 10.1038/nri3845 ID - Zitvogel2015 ER - TY - JOUR AU - Simmons, D. P. AU - Wearsch, P. A. AU - Canaday, D. H. AU - Meyerson, H. J. AU - Liu, Y. C. AU - Wang, Y. PY - 2012 DA - 2012// TI - Type I IFN drives a distinctive dendritic cell maturation phenotype that allows continued class II MHC synthesis and antigen processing JO - J Immunol VL - 188 UR - https://doi.org/10.4049/jimmunol.1101313 DO - 10.4049/jimmunol.1101313 ID - Simmons2012 ER - TY - JOUR AU - Parlato, S. AU - Santini, S. M. AU - Lapenta, C. AU - Pucchio, T. AU - Logozzi, M. AU - Spada, M. PY - 2001 DA - 2001// TI - Expression of CCR-7, MIP-3beta, and Th-1 chemokines in type I IFN-induced monocyte-derived dendritic cells: importance for the rapid acquisition of potent migratory and functional activities JO - Blood VL - 98 UR - https://doi.org/10.1182/blood.V98.10.3022 DO - 10.1182/blood.V98.10.3022 ID - Parlato2001 ER - TY - JOUR AU - Peng, D. AU - Kryczek, I. AU - Nagarsheth, N. AU - Zhao, L. AU - Wei, S. AU - Wang, W. PY - 2015 DA - 2015// TI - Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy JO - Nature VL - 527 UR - https://doi.org/10.1038/nature15520 DO - 10.1038/nature15520 ID - Peng2015 ER - TY - JOUR AU - Guillot, B. AU - Portales, P. AU - Thanh, A. D. AU - Merlet, S. AU - Dereure, O. AU - Clot, J. PY - 2005 DA - 2005// TI - The expression of cytotoxic mediators is altered in mononuclear cells of patients with melanoma and increased by interferon-alpha treatment JO - Br J Dermatol VL - 152 UR - https://doi.org/10.1111/j.1365-2133.2005.06512.x DO - 10.1111/j.1365-2133.2005.06512.x ID - Guillot2005 ER - TY - JOUR AU - Novikov, A. AU - Cardone, M. AU - Thompson, R. AU - Shenderov, K. AU - Kirschman, K. D. AU - Mayer-Barber, K. D. PY - 2011 DA - 2011// TI - Mycobacterium tuberculosis triggers host type I IFN signaling to regulate IL-1beta production in human macrophages JO - J Immunol VL - 187 UR - https://doi.org/10.4049/jimmunol.1100926 DO - 10.4049/jimmunol.1100926 ID - Novikov2011 ER - TY - JOUR AU - Bacher, N. AU - Raker, V. AU - Hofmann, C. AU - Graulich, E. AU - Schwenk, M. AU - Baumgrass, R. PY - 2013 DA - 2013// TI - Interferon-alpha suppresses cAMP to disarm human regulatory T cells JO - Cancer Res VL - 73 UR - https://doi.org/10.1158/0008-5472.CAN-12-3788 DO - 10.1158/0008-5472.CAN-12-3788 ID - Bacher2013 ER - TY - JOUR AU - Pantelidou, C. AU - Sonzogni, O. AU - Oliveira, T. M. AU - Mehta, A. K. AU - Kothari, A. AU - Wang, D. PY - 2019 DA - 2019// TI - PARP inhibitor efficacy depends on CD8+ T cell recruitment via intratumoral STING pathway activation in BRCA-deficient models of triple-negative breast cancer JO - Cancer Discov VL - 9 UR - https://doi.org/10.1158/2159-8290.CD-18-1218 DO - 10.1158/2159-8290.CD-18-1218 ID - Pantelidou2019 ER - TY - JOUR AU - Sen, T. AU - Rodriguez, B. L. AU - Chen, L. AU - Corte, C. M. D. AU - Morikawa, N. AU - Fujimoto, J. PY - 2019 DA - 2019// TI - Targeting DNA damage response promotes antitumor immunity through STING-mediated T-cell activation in small cell lung cancer JO - Cancer Discov VL - 9 UR - https://doi.org/10.1158/2159-8290.CD-18-1020 DO - 10.1158/2159-8290.CD-18-1020 ID - Sen2019 ER - TY - JOUR AU - Shen, J. AU - Zhao, W. AU - Ju, Z. AU - Wang, L. AU - Peng, Y. AU - Labrie, M. PY - 2019 DA - 2019// TI - PARPi Triggers the STING-dependent immune response and enhances the therapeutic efficacy of immune checkpoint blockade independent of BRCAness JO - Cancer Res VL - 79 UR - https://doi.org/10.1158/0008-5472.CAN-18-1003 DO - 10.1158/0008-5472.CAN-18-1003 ID - Shen2019 ER - TY - JOUR AU - Drapkin, B. J. AU - Farago, A. F. PY - 2019 DA - 2019// TI - Unexpected synergy reveals new therapeutic strategy in SCLC JO - Trends Pharmacol Sci VL - 40 UR - https://doi.org/10.1016/j.tips.2019.03.005 DO - 10.1016/j.tips.2019.03.005 ID - Drapkin2019 ER - TY - JOUR AU - Ding, W. AU - LaPlant, B. R. AU - Call, T. G. AU - Parikh, S. A. AU - Leis, J. F. AU - He, R. PY - 2017 DA - 2017// TI - Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL JO - Blood VL - 129 UR - https://doi.org/10.1182/blood-2017-02-765685 DO - 10.1182/blood-2017-02-765685 ID - Ding2017 ER - TY - JOUR AU - Gao, Y. AU - Yang, J. AU - Cai, Y. AU - Fu, S. AU - Zhang, N. AU - Fu, X. PY - 2018 DA - 2018// TI - IFN-gamma-mediated inhibition of lung cancer correlates with PD-L1 expression and is regulated by PI3K-AKT signaling JO - Int J Cancer VL - 143 UR - https://doi.org/10.1002/ijc.31357 DO - 10.1002/ijc.31357 ID - Gao2018 ER - TY - JOUR AU - Sato, H. AU - Niimi, A. AU - Yasuhara, T. AU - Permata, T. B. M. AU - Hagiwara, Y. AU - Isono, M. PY - 2017 DA - 2017// TI - DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells JO - Nat Commun VL - 8 UR - https://doi.org/10.1038/s41467-017-01883-9 DO - 10.1038/s41467-017-01883-9 ID - Sato2017 ER - TY - JOUR AU - Lee, A. J. AU - Ashkar, A. A. PY - 2018 DA - 2018// TI - The dual nature of Type I and Type II interferons JO - Front Immunol VL - 9 UR - https://doi.org/10.3389/fimmu.2018.02061 DO - 10.3389/fimmu.2018.02061 ID - Lee2018 ER - TY - JOUR AU - Chabanon, R. M. AU - Muirhead, G. AU - Krastev, D. B. AU - Adam, J. AU - Morel, D. AU - Garrido, M. PY - 2019 DA - 2019// TI - PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer JO - J Clin Invest VL - 129 UR - https://doi.org/10.1172/JCI123319 DO - 10.1172/JCI123319 ID - Chabanon2019 ER - TY - JOUR AU - Ding, L. AU - Kim, H. J. AU - Wang, Q. AU - Kearns, M. AU - Jiang, T. AU - Ohlson, C. E. PY - 2018 DA - 2018// TI - PARP unhibition elicits STING-dependent antitumor immunity in Brca1-deficient ovarian cancer JO - Cell Rep VL - 25 UR - https://doi.org/10.1016/j.celrep.2018.11.054 DO - 10.1016/j.celrep.2018.11.054 ID - Ding2018 ER - TY - JOUR AU - Criscuolo, D. AU - Morra, F. AU - Giannella, R. AU - Visconti, R. AU - Cerrato, A. AU - Celetti, A. PY - 2019 DA - 2019// TI - New combinatorial strategies to improve the PARP inhibitors efficacy in the urothelial bladder Cancer treatment JO - J Exp Clin Cancer Res VL - 38 UR - https://doi.org/10.1186/s13046-019-1089-z DO - 10.1186/s13046-019-1089-z ID - Criscuolo2019 ER - TY - JOUR AU - Wang, Z. AU - Sun, K. AU - Xiao, Y. AU - Feng, B. AU - Mikule, K. AU - Ma, X. PY - 2019 DA - 2019// TI - Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models JO - Sci Rep VL - 9 UR - https://doi.org/10.1038/s41598-019-38534-6 DO - 10.1038/s41598-019-38534-6 ID - Wang2019 ER - TY - JOUR AU - George, J. AU - Lim, J. S. AU - Jang, S. J. AU - Cun, Y. AU - Ozretic, L. AU - Kong, G. PY - 2015 DA - 2015// TI - Comprehensive genomic profiles of small cell lung cancer JO - Nature VL - 524 UR - https://doi.org/10.1038/nature14664 DO - 10.1038/nature14664 ID - George2015 ER - TY - JOUR AU - Byers, L. A. AU - Wang, J. AU - Nilsson, M. B. AU - Fujimoto, J. AU - Saintigny, P. AU - Yordy, J. PY - 2012 DA - 2012// TI - Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1 JO - Cancer Discov VL - 2 UR - https://doi.org/10.1158/2159-8290.CD-12-0112 DO - 10.1158/2159-8290.CD-12-0112 ID - Byers2012 ER - TY - JOUR AU - Karzai, F. AU - Madan, R. A. AU - Owens, H. AU - Couvillon, A. AU - Hankin, A. AU - Williams, M. PY - 2018 DA - 2018// TI - A phase 2 study of olaparib and durvalumab in metastatic castrate-resistant prostate cancer (mCRPC) in an unselected population JO - J Clin Oncol VL - 36 UR - https://doi.org/10.1200/JCO.2018.36.6_suppl.163 DO - 10.1200/JCO.2018.36.6_suppl.163 ID - Karzai2018 ER - TY - JOUR AU - Karzai, F. AU - VanderWeele, D. AU - Madan, R. A. AU - Owens, H. AU - Cordes, L. M. AU - Hankin, A. PY - 2018 DA - 2018// TI - Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations JO - J Immunother Cancer VL - 6 UR - https://doi.org/10.1186/s40425-018-0463-2 DO - 10.1186/s40425-018-0463-2 ID - Karzai2018 ER - TY - JOUR AU - Thomas, A. n. i. s. h. AU - Vilimas, R. a. s. a. AU - Trindade, C. h. r. i. s. t. o. p. h. e. r. AU - Erwin-Cohen, R. e. b. e. c. c. a. AU - Roper, N. i. t. i. n. AU - Xi, L. i. q. i. a. n. g. AU - Krishnasamy, V. e. n. k. a. t. e. s. h. AU - Levy, E. l. l. i. o. t. AU - Mammen, A. n. d. y. AU - Nichols, S. a. m. a. n. t. h. a. AU - Chen, Y. u. a. n. b. i. n. AU - Velcheti, V. a. m. s. i. d. h. a. r. AU - Yin, F. a. y. e. AU - Szabo, E. v. a. AU - Pommier, Y. v. e. s. AU - Steinberg, S. e. t. h. M. AU - Trepel, J. a. n. e. B. AU - Raffeld, M. a. r. k. AU - Young, H. o. w. a. r. d. A. AU - Khan, J. a. v. e. d. AU - Hewitt, S. t. e. p. h. e. n. AU - Lee, J. u. n. g. -. M. i. n. PY - 2019 DA - 2019// TI - Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II Study JO - Journal of Thoracic Oncology VL - 14 UR - https://doi.org/10.1016/j.jtho.2019.04.026 DO - 10.1016/j.jtho.2019.04.026 ID - Thomas2019 ER - TY - JOUR AU - Drew, Y. AU - Jonge, M. AU - Hong, S. H. AU - Park, Y. H. AU - Wolfer, A. AU - Brown, J. PY - 2018 DA - 2018// TI - An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed (PSR) ovarian cancer (OC) JO - Gynecol Oncol VL - 149 UR - https://doi.org/10.1016/j.ygyno.2018.04.555 DO - 10.1016/j.ygyno.2018.04.555 ID - Drew2018 ER - TY - JOUR AU - Vinayak, S. AU - Tolaney, S. M. AU - Schwartzberg, L. S. AU - Mita, M. M. AU - McCann, G. A. -. L. AU - Tan, A. R. PY - 2018 DA - 2018// TI - TOPACIO/Keynote-162: Niraparib + pembrolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC), a phase 2 trial JO - J Clin Oncol VL - 36 UR - https://doi.org/10.1200/JCO.2018.36.15_suppl.1011 DO - 10.1200/JCO.2018.36.15_suppl.1011 ID - Vinayak2018 ER - TY - JOUR AU - Konstantinopoulos, P. A. AU - Waggoner, S. E. AU - Vidal, G. A. AU - Mita, M. M. AU - Fleming, G. F. AU - Holloway, R. W. PY - 2018 DA - 2018// TI - TOPACIO/Keynote-162 (NCT02657889): A phase 1/2 study of niraparib + pembrolizumab in patients (pts) with advanced triple-negative breast cancer or recurrent ovarian cancer (ROC)—results from ROC cohort JO - J Clin Oncol VL - 36 UR - https://doi.org/10.1200/JCO.2018.36.15_suppl.106 DO - 10.1200/JCO.2018.36.15_suppl.106 ID - Konstantinopoulos2018 ER - TY - JOUR AU - Higuchi, T. AU - Flies, D. B. AU - Marjon, N. A. AU - Mantia-Smaldone, G. AU - Ronner, L. AU - Gimotty, P. A. PY - 2015 DA - 2015// TI - CTLA-4 blockade synergizes therapeutically with PARP inhibition in BRCA1-deficient ovarian cancer JO - Cancer Immunol Res VL - 3 UR - https://doi.org/10.1158/2326-6066.CIR-15-0044 DO - 10.1158/2326-6066.CIR-15-0044 ID - Higuchi2015 ER -